Edition:
India

Invion Ltd (IVX.AX)

IVX.AX on Australia Stock Exchange

0.01AUD
20 Oct 2020
Change (% chg)

$0.00 (+10.00%)
Prev Close
$0.01
Open
$0.01
Day's High
$0.01
Day's Low
$0.01
Volume
1,762,438
Avg. Vol
1,385,586
52-wk High
$0.03
52-wk Low
$0.01

Latest Key Developments (Source: Significant Developments)

Invion Says Craig Newton Will Retire As MD & CEO
Wednesday, 29 Jul 2020 

July 29 (Reuters) - Invion Ltd ::CRAIG NEWTON WILL RETIRE AS MD & CEO.ANTICIPATED CHAIRMAN, THIAN CHEW, WILL BECOME EXECUTIVE CHAIRMAN & INTERIM CEO FROM THAT TIME.EFFECTIVE DATE OF RETIREMENT FOR CRAIG NEWTON IS OCT 31.  Full Article

Invion Unit Signs Supply Agreement With Pavay Biotech
Tuesday, 30 Jun 2020 

June 30 (Reuters) - Invion Ltd ::UNIT SIGNS SUPPLY AGREEMENT WITH PAVAY BIOTECH.EPITECH WILL SUPPLY AUSTRALIAN-MADE PHOTOACTIVE INGREDIENTS TO PAVAY BIOTECH.EPITECH WILL SUPPLY PHOTOACTIVE INGREDIENTS FOR USE IN FORMULATION OF NEW RANGE OF DERMATOLOGY PRODUCTS.  Full Article

Invion Posts HY Loss Attributable Of $1.2 Million
Monday, 24 Feb 2020 

Feb 24 (Reuters) - Invion Ltd ::HY LOSS ATTRIBUTABLE $1.2 MILLION VERSUS LOSS OF $1.3 MILLION.HY REVENUE FROM CONTRACTS WITH CUSTOMERS $1.9 MILLION VERSUS $1.2 MILLION.  Full Article

Invion Signs Research Agreement With Peter Maccallum Cancer Centre
Thursday, 31 Oct 2019 

Oct 31 (Reuters) - Invion Ltd ::SIGNED RESEARCH AGREEMENT WITH PETER MACCALLUM CANCER CENTRE.UNDER AGREEMENT, PETER MAC WILL UNDERTAKE PRE-CLINICAL AND IN-VITRO STUDIES ON INVION'S IVX-PDT PHOTODYNAMIC THERAPY.  Full Article

Invion Confirms Craig Newton Will Commence In Role Of CEO Effective 1 Nov
Thursday, 24 Oct 2019 

Oct 24 (Reuters) - Invion Ltd ::INVION LTD - CONFIRMS CRAIG NEWTON WILL COMMENCE IN ROLE OF CHIEF EXECUTIVE OFFICER EFFECTIVE 1 NOVEMBER 2019.  Full Article

Invion Says Greg Collier Will Retire As MD And CEO
Monday, 22 Jul 2019 

July 22 (Reuters) - Invion Ltd ::CRAIG NEWTON WILL TRANSITION TO ROLE OF CHIEF EXECUTIVE OFFICER EFFECTIVE 1 NOVEMBER 2019.GREG COLLIER WILL RETIRE AS MD AND CEO.  Full Article

Invion Ltd Says Partnered With Co's To Formulate Gel Version Of Its Photosensitiser Product
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Invion Ltd ::INVION COLLABORATES TO DEVELOP POWERFUL SKIN CANCER GEL.COMPANY AIMS TO HAVE IVX-P02 GEL READY IN EARLY 2019 FOR TESTING IN HUMAN CLINICAL STUDIES.PARTNERED WITH TWO COMPANIES TO FORMULATE AND TEST A GEL VERSION OF ITS PHOTOSENSITISER PRODUCT, IVX-P02.DEVELOPMENT OF INJECTABLE IVX-P02 PHOTOSENSITISER IS ALSO PLANNED FOR TESTING IN SOLID CANCERS SUCH AS OVARIAN, PROSTATE AND LUNG CANCER.  Full Article

BRIEF-Invion Names Melanie Leydin As CFO

* NAMES MELANIE LEYDIN AS CFO Source text for Eikon: Further company coverage:

No consensus analysis data available.